Steroid and/or Prednisone Dependent Asthma | Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis

Steroid and/or Prednisone Dependent Asthma research study

What is the primary objective of this study?

The purpose of this study is to investigate whether addition of Omalizumab enables a reduction in the dose of prednisone in patients with asthma and eosinophilic bronchitis. This will be a double-blind placebo-controlled, 3-centre, randomized parallel group trial divided into two sequential study periods. Period 1: After establishing the minimum dose of prednisone to maintain asthma control and maintain sputum eosinophils <3%, subjects will be randomized to either placebo or Omalizumab for 16 weeks (either once monthly for 4 months or every 2 weeks for 4 months). Period 2: standardised prednisone reduction at intervals of 4-weeks until there is a clinical and eosinophilic exacerbation or bothersome steroid withdrawal effects. If patients have an exacerbation, they will be treated with prednisone. This patient will continue on Omalizumab or placebo during the entire duration of the study but not continue the phase of steroid reduction.

Who is eligible to participate?

Inclusion criteria 1. Confirmed asthma within the past 2 years (12% bronchodilator reversibility or PC20 methacholine less than 8 mg/ml) 2. ACQ ≥1.5 and sputum eos ≥3% at the time of randomization 3. On ICS (≥ 1500 mcg fluticasone propionate or equivalent) with or without additional prednisone 4. Total serum IgE ≥30 IU/L and positive allergy skin prick test 5. Age between 18 and 75 years 6. Ability to provide informed consent Exclusion criteria 1. Current smoker or ex-smokers with greater than 20 pack years 2. Co-morbid diseases which in the investigator's opinion would make the patient unsuitable to participate in the study 3. Currently on Omalizumab or has previously been treated with Omalizumab 4. Currently on other biologic therapies (eg. Prolia) 5. Pregnancy or lactation 6. Post bronchodilator FEV1 less than 50% predicted

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Steroid and/or Prednisone Dependent Asthma

Eosinophilic Bronchitis

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Biological:Omalizumab (Xolair)


Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

Omalizumab (Xolair)Dosage/frequency is dependent on body weight (kg) and baseline blood IgE level.

Placebo (Normal Saline)0.9% normal saline equivalent to the dosage/frequency/duration of Omalizumab

Study Status


Start Date: March 2014

Completed Date: September 2017

Phase: Phase 2/Phase 3

Type: Interventional


Primary Outcome: Proportion of patients with change in absolute % count of sputum eosinophil week 0 to week 12, and week 12 to week 32

Secondary Outcome: change in % sputum eosinophil

Study sponsors, principal investigator, and references

Principal Investigator: Parameswaran Nair, MD, PhD

Lead Sponsor: McMaster University

Collaborator: Novartis

More information:

Discuss Prednisone